Scholarlink

<p>The immunosuppressive tumor microenvironment and immune evasion mechanisms inhibit the development of effective antitumor responses and enduring immune memory, thereby diminishing the efficacy of cancer immunotherapy. In situ vaccines (ISVs) have been developed to overcome these challenges by inducing localized immunogenic cell death (ICD) and activating systemic immunity via dendritic cells (DCs) and CD8<sup>+</sup> T cells. In this study, we engineered ferrous sulfide–bovine serum albumin–cell membrane nanoclusters to trigger ferroptosis, which were co-encapsulated with the photothermal agent indocyanine green in a thermosensitive hydrogel. This platform enables near-infrared-responsive drug release and works with sorafenib to boost ferroptosis. Mechanistic studies revealed that this combined regimen markedly enhanced DC-mediated antigen presentation and CD8<sup>+</sup> T-cell infiltration, leading to substantial antitumor efficacy and complete eradication of distant liver metastases. Ultimately, the indocyanine green–ferrous sulfide–bovine serum albumin–cell membrane hydrogel–sorafenib system induces ferroptosis-driven ICD, promoting an ISV-like effect that activates systemic antitumor immunity and demonstrates strong therapeutic efficacy, suggesting its potential as a novel cancer treatment strategy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Ferroptosis-driven in situ vaccine-like antitumor effects: NIR-triggered IFBM hydrogel synergizes with sorafenib to unleash systemic antitumor immunity

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月8日

查看全文
  • Zilong Jiang,
  • Rui Fu,
  • Pengping Li,
  • Jiawei Zhang,
  • Yixian Cheng,
  • Kang Yang,
  • Junjie Chen,
  • Yaqi Zhang,
  • Lihua Su,
  • Yu Lei,
  • Bo Chen,
  • Guodong Cao

摘要

The immunosuppressive tumor microenvironment and immune evasion mechanisms inhibit the development of effective antitumor responses and enduring immune memory, thereby diminishing the efficacy of cancer immunotherapy. In situ vaccines (ISVs) have been developed to overcome these challenges by inducing localized immunogenic cell death (ICD) and activating systemic immunity via dendritic cells (DCs) and CD8+ T cells. In this study, we engineered ferrous sulfide–bovine serum albumin–cell membrane nanoclusters to trigger ferroptosis, which were co-encapsulated with the photothermal agent indocyanine green in a thermosensitive hydrogel. This platform enables near-infrared-responsive drug release and works with sorafenib to boost ferroptosis. Mechanistic studies revealed that this combined regimen markedly enhanced DC-mediated antigen presentation and CD8+ T-cell infiltration, leading to substantial antitumor efficacy and complete eradication of distant liver metastases. Ultimately, the indocyanine green–ferrous sulfide–bovine serum albumin–cell membrane hydrogel–sorafenib system induces ferroptosis-driven ICD, promoting an ISV-like effect that activates systemic antitumor immunity and demonstrates strong therapeutic efficacy, suggesting its potential as a novel cancer treatment strategy.